Breaking News

Pfizer Seeks Approval for Experimental COVID-19 Vaccine

May 4, 2021 • 6:51 am CDT
(Precision Vaccinations)

New York-based Pfizer Inc. published today its 'Key Near-term Potential Milestones for COVID-19 Vaccine Program (2021)' on slide #7 within its financial report.

This chart indicates Pfizer plans to file for full US Food and Drug Administration (FDA) Approval of its experimental COVID-19 vaccine (BNT162b2) in May 2021, about six months after receiving an FDA Emergency Use Authorization (EAU).

According to the FDA, the average time to Approve a new vaccine's Biologics License Application is about 10 months.

Furthermore, Pfizer may seek a EUA for vaccinating toddlers in November'21.

From a production capability perspective, Pfizer expects to manufacture at least 3 billion vaccine doses in 2022 (vs. 2.5B doses in 2021). Per Pfizer's slide #6, anticipated revenue from the Pfizer-BioNTech COVID-19 vaccine could reach $26 billion in 2021.

Medical Review by